Current stock page

Stock Analysis

Genmab A/S (GMAB) Stock Analysis

Genmab A/S (GMAB) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

GMAB Stock Analysis Summary

Genmab A/S (GMAB) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 94/100. Risk is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

GMAB at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$51.37
AIQ Score77/100
Overall ViewBullish
Technical Analysis ConsensusBuy
Market Cap$31.48B
P/E Ratio (TTM)42.8
Forward P/E—
EPS (Q3 FY2026)$0.56
Revenue (Q3 FY2026)$1.19B
Dividend Yield (TTM)0.00%
Beta0.93
Volume3.73M
52-week range$23.62-$59.97
RSI 1459.07
50-Day SMA$41.15
200-Day SMA$31.54
Analyst Price Target$55.50
Next EarningsFeb 16, 2027
As of Nov 13, 2026 · Market close

GMABGenmab A/S

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$51.37−$0.37 (−0.72%)

Latest quote

  • Momentum
    94
  • Value
    71
  • Quality
    72
  • Risk resilience
    58
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

GMAB Stock Analysis Summary

Genmab A/S (GMAB) currently has an AIQ Score of 77/100, indicating a bullish setup. Momentum is the strongest factor at 94/100. Risk resilience is the weakest current factor at 58/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Bullish

In a bullish regime, GMAB has AIQ Score of 77/100 with Momentum base of 94/100 and fading Risk resilience at 58/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (94/100) leads while Risk resilience (58/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.72% stock move · GMAB classified in Biotechnology.

Current Evidence

BullishGMAB is in a bullish AIQ regime; Momentum is the strongest visible factor at 94/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is GMAB Bullish or Bearish Right Now?

GMAB currently has a bullish overall setup. Momentum is the strongest factor at 94/100, while Risk Resilience is weakest at 58/100. The current evidence suggests a constructive setup.

Bull Case
  • - Quality is supportive at 72/100.
  • - Momentum is constructive at 94/100.
  • - Price is +24.83% above its 50-day SMA.
  • - Analyst target implies +8.04% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (25 vs 14).
Bear Case
  • - No strong bearish evidence is available in the current snapshot.

Current Consensus

GMAB's Technical Analysis Consensus is currently Buy, with 25 buy, 7 neutral, and 14 sell votes. GMAB's 14-day RSI is 59.07, which places the stock in a constructive momentum range. GMAB's beta is 0.93, indicating market sensitivity broadly in line with the market.

Signal Confidence
Moderate agreement

What Changed in GMAB?

The largest recent change in GMAB is Momentum moving down by 4.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-4.0
Quality
+0.0
Risk
+0.0

What Would Change the GMAB Outlook?

The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

GMAB Decision Framework

Public evidence layers, setup checks, and risk context for Genmab A/S.

Genmab A/S (GMAB) Stock Analysis

Genmab A/S has an AIQ Score of 77/100 in a Bullish regime. Momentum is strongest at 94/100. Beta is 0.93, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextGMAB is in a Bullish AIQ regime with score 77/100.
Signal ConflictThe primary conflict is that momentum leads at 94/100 while risk lags at 58/100.
Factor EvidenceMomentum 94/100 · Value 71/100 · Quality 72/100 · Risk 58/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 94/100.

TimingPass

Momentum is 94/100 and RSI (14) is 59.1.

Regime fitPass

GMAB is in a Bullish regime at 77/100.

Risk controlWait

Risk factor is 58/100 with beta 0.93 and annual volatility 45.85%.

ConflictWait

Current conflict: momentum leads at 94/100 while risk lags at 58/100.

AIQ Score
77/100
Price
$51.37
Beta
0.93
RSI (14)
59.1

GMAB Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

GMAB Fundamentals

GMAB valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$1.19B
Net income
$342M
Free cash flow
$509M
View full GMAB fundamental analysis

GMAB Technical Analysis

GMAB technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Buy
RSI 14
59.07
Price vs SMA-50
+24.83%
View full GMAB technical analysis

GMAB Stock Catalysts

Track GMAB earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 16, 2027
Analyst target
$55.50
News items
4
View GMAB earnings and stock catalysts

GMAB Dividend Analysis

GMAB dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View GMAB dividend history and analysis

GMAB Financial Data

GMAB revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$1.19B
EPS
$0.56
Periods
8
View GMAB financials

GMAB Risk Analysis

GMAB volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.93
Risk score
58/100
1Y volatility
45.85%
View GMAB risk analysis

GMAB Stock News

GMAB stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read GMAB stock news

GMAB vs Biotechnology Peers

Current peer cohort: GMAB · HALO · HRMY · IDYA · IMNM. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
GMAB
Current stock
77/10071/10094/10058/1001.2945.85%Current
HALO
Halozyme Therapeutics, Inc.
78/10076/10084/10063/1000.9541.04%GMAB vs HALO
HRMY
Harmony Biosciences Holdings, Inc.
73/10089/10066/10063/1000.0740.59%GMAB vs HRMY
IDYA
IDEAYA Biosciences, Inc.
54/10039/10063/10061/1000.1444.94%GMAB vs IDYA
IMNM
Immunome, Inc.
48/100—45/10047/1000.4560.72%GMAB vs IMNM
Pairwise Compare links: HALO · HRMY · IDYA · IMNMGMAB vs HALOGMAB vs HRMYGMAB vs IDYAGMAB vs IMNMCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a GMAB stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for GMAB: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
42.8
As of Nov 13, 2026
Revenue growth
16.14%
Gross margin
92.60%
Current debt / equity
0.82
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$1.19B
Quarter net income
$342M
Quarter free cash flow
$509M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Mixed
RSI 14
59.07
MACD
3.86

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
58/100
Beta
0.93
Annual volatility
45.85%
Max drawdown
-32.51%

GMAB Stock FAQ

What is GMAB stock price today?

Genmab A/S's current stock price is $51.37. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is GMAB bullish or bearish right now?

GMAB's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is GMAB's market cap?

GMAB's market cap is $31.48B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is GMAB's current P/E ratio?

GMAB's current P/E ratio is 42.8 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is GMAB's RSI?

GMAB's 14-day RSI is 59.07 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is GMAB above its 50-day and 200-day moving averages?

GMAB is 24.83% from its 50-day SMA and 62.87% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is GMAB's next earnings date?

GMAB's next earnings date is currently listed as Feb 16, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does GMAB pay a dividend?

GMAB's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.